Clin Osteol 2018; 23(1): 28-31
Secondary osteoporosis associated with cancer therapy: a standard diagnostic and therapeutic procedure concerning patients with cancer treatment induced bone lossGuidelines
- 1 Spoločnos» pre osteoporózu a metabolické ochorenia kostí
- 2 Interná-osteologická ambulancia, Onkologický ústav sv. Alľbety, s. r. o., Bratislava
- 3 V. interná klinika, LF UK a UNB, Nemocnica Ruľinov, Bratislava
- 4 II. onkologická klinika, LF UK a Národný onkologický ústav, Bratislava
The Ministry of Health in cooperation with specialists has been actively engaged in the creation of standard preventive, diagnostic and therapeutic procedures. The standard diagnostic and therapeutic procedures provide a rough guide to the treatment for a diagnosis in question. The Society for Osteoporosis and Metabolic Bone Diseases has prepared a standard diagnostic and therapeutic procedure concerning patients with postmenopausal osteoporosis.
Key words:
androgen-deprivation therapy - bisphosphonates - denosumab - hormonal manipulation - aromatase inhibitors - osteoporosis - cancer treatment - zolendronate
Received 6. 8. 2018
Published: June 11, 2018 Show citation
| ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |
©pániková B, Payer J, Jackuliak P, Mego M. Secondary osteoporosis associated with cancer therapy: a standard diagnostic and therapeutic procedure concerning patients with cancer treatment induced bone loss. Clinical Osteology. 2018;23(1):28-31.
References
- Body JJ, Bergmann P, Boonen S et al. Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications. Osteoporosis Int 2012; 23(Suppl 1): S1-S23.
Go to original source... - Early Breast Cancer Trialists Collaborative Group (EBCTCG). Adjuvant bisfosofnate treatement in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 2015; 386(10001): 1353-1361. Go to original source...
- Gnant M, Pfeiler G, Dubsky PC et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015; 386(9992): 433-443. Go to original source...
- Hadji P, Aapro MS, Body JJ et al. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol 2017; 7 : 1-12. Dostupné z DOI: <http://doi:10.1016/j.jbo.2017.03.001>. Go to original source...
- Hadji P, Coleman RE,Wilson C et al. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Ann Oncol 2016; 27(3): 379-390. Go to original source...
- Lipton A, Smith MR, Ellis GK et al. Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab. Clin Med Insights Oncol 2012; 6 : 287-303. Dostupné z DOI: <http://doi:10.4137/CMO.S8511>. Go to original source...
- Morin JP, Domenech AC, Santos JP. Bone mass behavior after 1 year of different treatment strategies in prostate cancer patients subjected to androgen deprivation therapy. Rheumatol Int 2014; 34(10): 1419-1425. Go to original source...
- Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001; 19(14): 3306-3311. Go to original source...
- Smith MR, Egerdie B, Toriz NH et al. Denosumab in men Receving androgen-deprivation therapy for prostate cancer. New England Journal of Medicine 2009; 36(8): 745-755. Go to original source...